Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia

Haemophilia

Volumn 14, Issue 4, 2008, Pages 736-742

  Dehmel, H ^a   Werwitzke, S ^a   Trummer, A ^a   Ganser, A ^a   Tiede, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acquired haemophilia; Factor VIII; Inhibitor; Pharmacodynamic monitoring; Recombinant factor VIIa (NovoSeven)

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; HEMOPHILIA; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; STEADY STATE; SURGICAL PATIENT; THROMBOELASTOGRAPHY;

AGED; AGED, 80 AND OVER; COAGULANTS; DRUG MONITORING; FACTOR VIIA; FEMALE; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REFERENCE VALUES; THROMBELASTOGRAPHY; TREATMENT OUTCOME;

EID: 47649108091     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01759.x     Document Type: Article

References (21)

1. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
2. Berntorp E, Gringeri A, Leissinger C, Negrier C, Key N. New approaches to using FEIBA in the treatment of inhibitor patients. Semin Thromb Hemost 2006; 32(Suppl. 2): 22-7.
3. Turecek PL, Varadi K, Gritsch H et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77(Suppl. 1): 72-9.
4. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006; 32(Suppl. 1): 77-85.
5. Johannessen M, Nielsen G, Nordfang O. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S159-64.
6. Goudemand J, Caron C, Dreyfus M, Sie P. Standardization of factor VII/ activated factor VII measurement in plasma of patients treated with recombinant factor activated VII. Blood Coagul Fibrinolysis 2003; 14: 505-11.
7. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996; 26(Suppl. 1): 102-8.
8. Smith MP, Ludlam CA, Collins PW et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: Plasma factor VII activity of 10IU/mL is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53.
9. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
10. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
11. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81-90.
12. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
13. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
14. Varadi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
15. Wegert W, Harder S, Bassus S, Kirchmaier CM. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant factor VIIa. Platelets 2005; 16: 45-50.
16. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997; 78: 1463-7.
17. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
18. Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: Results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255-9.
19. Baudo F, de Cataldo F, Gaidano G. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: Data from the Italian registry of acquired hemophilia. Haematologica 2004; 89: 759-61.
20. Johansen RF, Sorensen B, Ingerslev J. Acquired haemophilia: Dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia 2006; 12: 190-7.
21. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.